Pleural diseases in the molecular era-time for more answers: Introduction

Respiration

Volumn 83, Issue 1, 2012, Pages 2-4

  Froudarakis, Marios E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; MATRIX METALLOPROTEINASE; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EDITORIAL; GENE THERAPY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NARROW BAND IMAGING; PLEURA DISEASE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURA METASTASIS; PLEURODESIS; PNEUMOTHORAX; PRIMARY SPONTANEOUS PNEUMOTHORAX; PRIORITY JOURNAL; PROGNOSIS;

BIOLOGICAL MARKERS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PLEURAL DISEASES;

EID: 84856001972     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000334743     Document Type: Editorial

References (29)

1. Froudarakis ME: Diagnostic work-up of pleura l ef fusions. Respiration 2008; 75: 4-13.
2. Sriram KB, Relan V, Clarke BE, Duhig EE, Yang IA, Bowman RV, Lee YC, Fong KM: Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol 2011; 7: 737-752.
3. Froudarakis ME: New challenges in medical thoracoscopy. Respiration 2011; 82: 197-200.
4. Froudarakis ME, Noppen M: Medical thora-coscopy: new tricks for an old trade. Respiration 2009; 78: 373-374.
5. Cordier JF: Orphan diseases, rare diseases, time to get mobilised (in French). Rev Prat 2006; 56: 123-124.
6. Froudarakis ME, Briasoulis E: Advanced non-small cell lung cancer: on relapse re-challenge the tumor, not the patient. BMC Res Notes 2010; 3: 195.
7. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol 2007; 2:706-714. (Pubitemid 47357522)
8. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K: Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997; 3:47-50. (Pubitemid 27079443)
9. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P: The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007; 2:1067-1077. (Pubitemid 350307898)
10. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Pechoux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-495.
11. van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P: Malignant pleural mesothelio-ma: the standard of care and challenges for future management. Crit Rev Oncol Hema-tol 2011; 78:92-111.
12. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O'Brien M, Thomas G, Senan S, O'Byrne K, Kilburn LS, Spicer J, Landau D, Edwards J, Coombes G, Darlison L, Peto J: Extra-pleural pneumonectomy versus no extra-pleural pneumo-nectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Me-sothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011; 12:763-772.
13. Aelony Y: Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage. J Clin Oncol 2006; 24: 4667, author reply 4667-4668. (Pubitemid 46630966)
14. Markman M, Cleary S, Pfeifle C, Howell SB: Cisplatin administered by the intracavitary route as treatment for malignant mesotheli-oma. Cancer 1986; 58: 18-21. (Pubitemid 16093097)
15. Astoul P, Picat-Joossen D, Viallat JR, Boutin C: Intrapleural administration of interleu-kin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998; 83:2099-2104. (Pubitemid 28525391)
16. Greillier L, Monjanel-Mouterde S, Fraticelli A, Devictor-Pierre B, Bouvenot J, Coltel N, Lamarche G, Astoul P: Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. J Thorac Oncol 2009; 4: 404-408.
17. Froudarakis ME, Greillier L, Monjanel-Mouterde S, Koutsopoulos A, Devictor-Pierre B, Guilhaumou R, Karpathiou G, Botaitis S, Astoul P: Intrapleural administration of lipoplatin in an animal model. Lung Cancer 2011; 72:78-83.
18. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, Ho M, Pastan I, Machuzak M, Benedict W, Zhang XQ, Lord EM, Litzky LA, Heitjan DF, June CH, Kaiser LR, Vonderheide RH, Albelda SM, Kanther M: A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13: 4456-4466. (Pubitemid 47219714)
19. Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Papasavvas E, Montaner LJ, Heitjan DF, Litzky L, Friedberg J, Culligan M, June CH, Carroll RG, Albelda SM: A trial of intrapleural adenoviral-mediated inter-feron-{alpha}2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011, E-pub ahead of print.
20. Ishida A, Ishikawa F, Nakamura M, Miyazu YM, Mineshita M, Kurimoto N, Koike J, Nishisaka T, Miyazawa T, Astoul P: Narrow band imaging applied to pleuroscopy for the assessment of vascular patterns of the pleura. Respiration 2009; 78: 432-439.
21. Psathakis K, Calderon-Osuna E, Romero-Romero B, Martin-Juan J, Romero-Falcon A, Rodriguez-Panadero F: The neutrophilic and fibrinolytic response to talc can predict the outcome of pleurodesis. Eur Respir J 2006; 27:817-821. (Pubitemid 44914208)
22. Froudarakis ME, Klimathianaki M, Pougounias M: Systemic inflammatory reaction after thoracoscopic talc poudrage. Chest 2006; 129: 356-361. (Pubitemid 43289855)
23. Nasreen N, Mohammed KA, Dowling PA, Ward MJ, Galffy G, Antony VB: Talc induces apoptosis in human malignant mesothelio-ma cells in vitro. Am J Respir Crit Care Med 2000; 161: 595-600. (Pubitemid 30129472)
24. Nasreen N, Mohammed KA, Brown S, Su Y, Sriram PS, Moudgil B, Loddenkemper R, Antony VB: Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J 2007; 29: 761-769. (Pubitemid 46554628)
25. Tschopp JM, Rami-Porta R, Noppen M, Astoul P: Management of spontaneous pneu-mothorax: state of the art. Eur Respir J 2006; 28:637-650. (Pubitemid 44794681)
26. Noppen M, Dekeukeleire T, Hanon S, Stratakos G, Amjadi K, Madsen P, Meysman M, D'Haese J, Vincken W: Fluorescein-en-hanced autofluorescence thoracoscopy in patients with primary spontaneous pneumo-thorax and normal subjects. Am J Respir Crit Care Med 2006; 174: 26-30. (Pubitemid 43955241)
27. Noppen M, Stratakos G, Verbanck S, D'Haese J, Meysman M, Vincken W: Fluorescein-en-hanced autofluorescence thoracoscopy in primary spontaneous pneumothorax. Am J Respir Crit Care Med 2004; 170:680-682. (Pubitemid 39202211)
28. Noppen M, De Keukeleire T: Pneu mothora x. Respiration 2008; 76:121-127.
29. De Smedt A, Vanderlinden E, Demanet C, De Waele M, Goossens A, Noppen M: Characterisation of pleural inflammation occurring after primary spontaneous pneumotho-rax. Eur Respir J 2004; 23: 896-900. (Pubitemid 38807365)